It was a pleasure to speak with Dr Andrew Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the JADE REGIMEN Phase 3 trial (NCT03627767) investigating abrocitinib in patients with atopic dermatitis.
The abstract entitled ‘Abrocitinib Induction, Randomized Withdrawal and Response Recapture With Rescue Therapy in Patients With Moderate-to-Severe Atopic Dermatitis: Results From the JADE REGIMEN Phase 3 Trial’ was presented at AAD VMX, 23-25 April 2021.
- What is the rationale for the use of abrocitinib in the treatment of adults with moderate to severe atopic dermatitis? (0:14)
- Could you tell us about the unique design of the JADE REGIMEN Phase 3 study? (0:55)
- What was the response to abrocitinib in the induction, maintenance and rescue periods? (3:09)
- What was the safety profile of abrocitinib, and how can adverse events be minimized? (4:52)
- What are the significance of these findings in terms of the evolving treatment paradigm for atopic dermatitis? (6:18)
Disclosures: Dr. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Atopic Dermatitis
Kim Papp, AAD VMX 2021: Ruxolitinib Phase 3 Subgroup Analysis
It was a pleasure to speak with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) around the efficacy and tolerability of ruxolitinib cream in the treatment of atopic dermatitis (NCT03745638 & NCT03745651). The abstract ‘Efficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis by Baseline Clinical Characteristics: Pooled Subgroup Analysis From Two Randomized […]
Amy S. Paller, AAD VMX: Dupilumab LIBERTY AD PEDS Trial
We were delighted to speak with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) about the results from the phase 3, LIBERTY AD PEDS trial (NCT03345914). This double-blind, 16-week study investigated duplimuab in children with atopic dermatitis. Her abstract entitled ‘Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, […]
Amy S. Paller, AAD VMX: Advances in the Treatment of Atopic Dermatitis in Children
Following the AAD VMX meeting we caught up with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss some of the presentations and recent advances being made in the treatment of children with atopic dermatitis. Disclosures: Prof. Amy Paller has acted as a consultant with honorarium for AbbVie, Abeona, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!